These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38677640)

  • 1. Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
    Guo X; Yang Y; Qian Z; Chang M; Zhao Y; Ma W; Wang Y; Xing B
    Cancer Lett; 2024 Jun; 592():216908. PubMed ID: 38677640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset.
    Luo M; Tang R; Wang H
    J Neurooncol; 2023 Jul; 163(3):663-674. PubMed ID: 37418134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
    Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
    CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.
    Lin S; Dai Y; Han C; Han T; Zhao L; Wu R; Liu J; Zhang B; Huang N; Liu Y; Lai S; Shi J; Wang Y; Lou M; Xie J; Cheng Y; Tang H; Yao H; Fang H; Zhang Y; Wu X; Shen L; Ye Y; Xue L; Wu ZB
    Genome Med; 2024 Apr; 16(1):60. PubMed ID: 38658971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Immune Microenvironment Landscape of Pituitary NeuroEndocrine Tumors, a Transcriptomic Approach.
    Vela-Patiño S; Salazar MI; Taniguchi-Ponciano K; Vadillo E; Gomez-Apo E; Escobar-España A; Perez-Koldenkova V; Bonifaz L; Aguilar-Flores C; Marrero-Rodríguez D; Mercado M
    Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
    Turchini J; Sioson L; Clarkson A; Sheen A; Gill AJ
    Endocr Pathol; 2021 Sep; 32(3):408-414. PubMed ID: 33694064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
    Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
    Luo P; Zhang L; Yang L; An Z; Tan H
    Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of biomarkers associated with the invasion of nonfunctional pituitary neuroendocrine tumors based on the immune microenvironment.
    Wu J; Guo J; Fang Q; Liu Y; Li C; Xie W; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1131693. PubMed ID: 37522128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
    Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
    Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas.
    Cossu G; La Rosa S; Brouland JP; Pitteloud N; Harel E; Santoni F; Brunner M; Daniel RT; Messerer M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage colony-stimulating factor potentially induces recruitment and maturation of macrophages in recurrent pituitary neuroendocrine tumors.
    Matsuzaki H; Komohara Y; Yano H; Fujiwara Y; Kai K; Yamada R; Yoshii D; Uekawa K; Shinojima N; Mikami Y; Mukasa A
    Microbiol Immunol; 2023 Feb; 67(2):90-98. PubMed ID: 36461910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.